Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capillar Equity Investment I on its sale of shares in Nordic Surface Group
Mandate

Vinge advises Capillar Equity Investment I on its sale of shares in Nordic Surface Group

January 15, 2021 M&A

Vinge is advising Capillar Equity Investment I in connection with the sale of shares in Nordic Surface Group (“NSG”) to a funds managed by Litorina and Bragnum, respectivley. NSG’s management will remain as significant co-owners in the group consisting of six local market leaders formed by Capillar Equity in 2020.

The company offers painting and other surface services such as flooring, tiling and facade finishing in Sweden and combined reported a revenue of SEK 1bn with 800 FTEs in 2020.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

The Vinge team advising on the transaction includes partner Christina Kokko with the associates Michaela Cronemyr, Johanna Wiberg and Ellinor Wargenbrant.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026